<DOC>
	<DOC>NCT01720251</DOC>
	<brief_summary>The main objective of the trial is to demonstrate the efficacy of a two months pre-seasonal treatment with AllerT 100 µg maintenance dose in reducing symptoms of allergic rhinoconjunctivitis during the following birch pollen season</brief_summary>
	<brief_title>Efficacy Study of a Preseasonal Treatment With AllerT in Subjects With Birch Pollen Allergy</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>moderate to severe allergic rhinoconjunctivitis to birch pollen: 1. Score of symptoms of the Rhinoconjunctivitis Symptom Score (RSS) ≥ 12 during the two preceding birch pollen seasons 2. Previous use of antiallergy medications during the two preceding birch pollen seasons 3. Positive SPT to birch pollen extract 4. Positive specific IgE CAP test for Bet v 1 uncontrolled asthma, FEV1 &lt; 80% of predicted previous SIT (specific immunotherapy) to birch pollen or any other SIT within 5 years clinical symptoms due to allergens other than birch pollen during the whole trial period history of anaphylaxis positive skin prick test to AllerT any other treatment or conditions which may increase the risk of the study for the subject or affect the efficacy assessments during the birch pollen season</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>allergic rhinitis</keyword>
	<keyword>birch pollen</keyword>
	<keyword>immunotherapy</keyword>
</DOC>